Perinatal and Hemodynamic Evaluation of Sildenafil Citrate for Preeclampsia Treatment

Obstetrics and Gynecology

Volumn 128, Issue 2, 2016, Pages 253-259

  Trapani, Alberto ^a   Gonçalves, Luis Flavio ^a   Trapani, Thamyris Finger ^a   Vieira, Simone ^a   Pires, Marilen ^a   Pires, Maria Marlene De Souza ^a  

^a UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SILDENAFIL; PHOSPHODIESTERASE V INHIBITOR;

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; ECLAMPSIA; EPIGASTRIC PAIN; FEMALE; FETUS CIRCULATION; FLUSHING; GESTATION PERIOD; HEADACHE; HELLP SYNDROME; HEMOLYSIS; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MATERNAL BLOOD; MIDDLE CEREBRAL ARTERY; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PERINATAL MORBIDITY; PERINATAL MORTALITY; PLACENTA CIRCULATION; POSTPARTUM HEMORRHAGE; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOLUTIO PLACENTAE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; UMBILICAL ARTERY; UTERINE ARTERY; VISUAL DISORDER; VOMITING; BLOOD FLOW VELOCITY; BLOOD PRESSURE; DIAGNOSTIC IMAGING; DOPPLER ULTRASONOGRAPHY; DRUG EFFECTS; GESTATIONAL AGE; PATHOPHYSIOLOGY; PRE-ECLAMPSIA; TIME FACTOR; VASCULAR RESISTANCE; YOUNG ADULT;

ADULT; BLOOD FLOW VELOCITY; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; GESTATIONAL AGE; HUMANS; MIDDLE CEREBRAL ARTERY; PHOSPHODIESTERASE 5 INHIBITORS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY MAINTENANCE; SILDENAFIL CITRATE; TIME FACTORS; ULTRASONOGRAPHY, DOPPLER; UMBILICAL ARTERIES; UTERINE ARTERY; VASCULAR RESISTANCE; YOUNG ADULT;

EID: 84978120378     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000001518     Document Type: Article

References (30)

1. Executive summary: hypertension in pregnancy. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;122:1122-31
2. Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol 1994;171:818-22
3. Haddad B, Deis S, Goffinet F, Paniel BJ, Cabrol D, Sibai BM. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation. Am J Obstet Gynecol 2004;190:1590-5
4. Manktelow BN, Seaton SE, Field DJ, Draper ES. Populationbased estimates of in-unit survival for very preterm infants. Pediatrics 2013;131:e425-32
5. Robertson SA, Ingman WV, O'Leary S, Sharkey DJ, Tremellen KP. Transforming growth factor beta-A mediator of immune deviation in seminal plasma. J Reprod Immunol 2002;57:109-28
6. Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996;175:1365-70
7. McKeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004; 191:1240-6
8. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12
9. Learmont JG, Poston L. Nitric oxide is involved in flowinduced dilation of isolated human small fetoplacental arteries. Am J Obstet Gynecol 1996;174:583-8
10. Lees C, Valensise H, Black R, Harrington K, Byiers S, Romanini C, et al. The efficacy and fetal-maternal cardiovascular effects of transdermal glyceryl trinitrate in the prophylaxis of preeclampsia and its complications: a randomized doubleblind placebo-controlled trial. Ultrasound Obstet Gynecol 1998;12:334-8
11. Trapani A Jr, Gonçalves LF, Pires MM. Transdermal nitroglycerin in patients with severe pre-eclampsia with placental insufficiency: effect on uterine, umbilical and fetal middle cerebral artery resistance indices. Ultrasound Obstet Gynecol 2011;38: 389-94
12. Wareing M, Myers JE, O'Hara M, Baker PN. Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. J Clin Endocrinol Metab 2005;90:2550-5
13. Cauli O, Herraiz S, Pellicer B, Pellicer A, Felipo V. Treatment with sildenafil prevents impairment of learning in rats born to pre-eclamptic mothers. Neuroscience 2010;171:506-12
14. Coppage KH, Sun X, Baker RS, Clark KE. Expression of phosphodiesterase 5 in maternal and fetal sheep. Am J Obstet Gynecol 2005;193:1005-10
15. Samangaya RA, Mires G, Shennan A, Skillern L, Howe D, McLeod A, et al. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy 2009; 28:369-82
16. Trapani AJ, Gonçalves LF, Trapani TF, Franco MJ, Galluzzo RN, Pires MM. Comparison between transdermal nitroglycerin and sildenafil citrate in intrauterine growth restriction: effect on uterine, umbilical and fetal middle cerebral artery pulsatility index. Ultrasound Obstet Gynecol 2015 Aug 17 [Epub ahead of print]
17. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57
18. Fetal growth restriction. Practice Bulletin No. 134. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;121:1122-33
19. Vigil-Gracia P, Reyes Tejada O, CalleMiñaca A, Tellez G, Chon VY, Herrarte E, et al. Expectant management of severe preeclampsia remote from term: a randomized, multicentre clinical trial: the MEXPRE Latin Study. Am J Obstet Gynecol 2013;209:425.e1-8
20. Panda S, Das A, Md Nowroz H. Sildenafil citrate in fetal growth restriction. J Reprod Infertil 2014;15:168-9
21. Lin TH, Su YN, Shih JC, Hsu HC, Lee CN. Resolution of high uterine artery pulsatility index and notching following sildenafil citrate treatment in a growth-restricted pregnancy. Ultrasound Obstet Gynecol 2012;40:609-10
22. Dastjerdi MV, Hosseini S, Bayani L. Sildenafil citrate and uteroplacental perfusion in fetal growth restriction. J Res Med Sci 2012;17:632-6
23. Luzi G, Caserta G, Iammarino G, Clerici G, Di Renzo GC. Nitric oxide donors in pregnancy: fetomaternal hemodynamic effects induced in mild preeclampsia and threatened preterm labor. Ultrasound Obstet Gynecol 1999;14:101-9
24. Cacciatore B, Halmesmäki E, Kaaja R, Teramo K, Ylikorkala O. Effects of transdermal nitroglycerin on impedance to flow in the uterine, umbilical, and fetal middle cerebral arteries in pregnancies complicated by preeclampsia and intrauterine growth retardation. Am J Obstet Gynecol 1998;179:140-5
25. Lain KY, Roberts JM. Contemporary concepts of the pathogenesis and management of preeclampsia. JAMA 2002;287:3183-6
26. Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T, Karumanchi SA, et al. Removal of soluble fmslike tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J Am Soc Nephrol 2016;27:903-13
27. Cleary KL, Roney K, Costantine M. Challenges of studying drugs in pregnancy for off-label indications: pravastatin for preeclampsia prevention. Semin Perinatol 2014;38:523-7
28. Conrad KP, Davison JM. The renal circulation in normal pregnancy and preeclampsia: is there a place for relaxin? Am J Physiol Renal Physiol 2014;306:F1121-35
29. Cooke CL, Davidge ST. Peroxynitrite increases iNOS through NF-kappaB and decreases prostacyclin synthase in endothelial cells. Am J Physiol Cell Physiol 2002;282:C395-402
30. Dadelszen P, Dwinnell S, Magee LA, Carleton BC, Gruslin A, Lee B, et al. Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG 2011;118: 624-8